Elevation Oncology’s Claudin 18.2 ADC, EO-3021: Latest Developments and What They Mean
Elevation Oncology, a leading oncology company, has announced significant progress in its Claudin 18.2 Antibody-Drug Conjugate (ADC), EO-3021, and other pipeline candidates. Here’s a closer look at the recent updates and their potential implications.
EO-3021 in Advanced Gastric/GEJ Cancer: Combination Trials and Expected Data
In the latest announcement, Elevation Oncology shared that the ongoing Phase 1 clinical trial cohorts evaluating EO-3021 in combination with ramucirumab or dostarlimab for advanced gastric/gastroesophageal junction (GEJ) cancer are progressing well. The company anticipates reporting initial data from these combination cohorts in the last quarter of 2025 or the first quarter of 2026.
Additionally, Elevation Oncology expects to report additional monotherapy data from the dose escalation and expansion cohort of the ongoing Phase 1 clinical trial in the second quarter of 2025.
Preclinical Data for HER3 ADC, EO-1022, and IND Application
Furthermore, the company plans to present preclinical data for its HER3 ADC, EO-1022, at the American Association for Cancer Research (AACR) Annual Meeting 2025. Elevation Oncology intends to file an Investigational New Drug (IND) application for EO-1022 in 2026.
What Does This Mean for Patients and the World?
For patients with advanced gastric/GEJ cancer, these developments could potentially lead to new treatment options with improved efficacy and fewer side effects, as ADCs are designed to target specific cancer cells while minimizing damage to healthy cells.
Globally, this progress in targeted cancer therapies could contribute to better patient outcomes, longer survival rates, and reduced healthcare costs associated with managing advanced gastric/GEJ cancer.
Elevation Oncology’s Financial Results and Business Achievements
Beyond these pipeline updates, Elevation Oncology announced its financial results for the quarter and full-year ended December 31, 2024. The company reported a net loss attributable to common stockholders of $13.3 million for the fourth quarter and $56.9 million for the full year. Elevation Oncology’s cash, cash equivalents, and restricted cash were $128.1 million as of December 31, 2024.
Conclusion
Elevation Oncology’s progress in the development of its Claudin 18.2 ADC, EO-3021, and HER3 ADC, EO-1022, presents promising opportunities for patients with advanced gastric/GEJ cancer. As the company continues to advance these programs and file IND applications, the global oncology community eagerly awaits the potential benefits these treatments could bring.
- EO-3021 in combination trials with ramucirumab and dostarlimab for advanced gastric/GEJ cancer: Initial data expected in 4Q 2025 or 1Q 2026
- Additional monotherapy data from Phase 1 clinical trial to be reported in 2Q 2025
- Preclinical data for HER3 ADC, EO-1022, to be presented at AACR Annual Meeting 2025
- IND application for EO-1022 planned for 2026
- Net loss attributable to common stockholders for Q4 and FY 2024: $13.3 million and $56.9 million, respectively
- Cash, cash equivalents, and restricted cash as of December 31, 2024: $128.1 million
